Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MYM V101

Drug Profile

MYM V101

Alternative Names: HIV gp41 vaccine - Mymetics; Mucosal HIV/AIDS vaccine - Mymetics; MYM-V101; MYM-V201; Second generation virosome-based HIV vaccine - Mymetics; Virosome-gp41 mucosal vaccine - Mymetics

Latest Information Update: 02 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mymetics Corporation
  • Developer Mymetics Corporation; Texas Biomedical Research Institute
  • Class AIDS vaccines; Antivirals
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 30 Apr 2019 Mymetics in collaboration Texas Biomedical Research Institute and University of Louisiana at Lafayette plans clinical trials in HIV infections
  • 28 Nov 2018 No recent reports of development identified for preclinical development in HIV-infections(Prevention) in USA (IM, Injection)
  • 14 Nov 2018 Preclinical trials in HIV infections (Prevention) in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top